Literature DB >> 32902889

The emerging SARS-CoV-2 papain-like protease: Its relationship with recent coronavirus epidemics.

Mahmoud Kandeel1,2, Yukio Kitade3,4, Mahmoud Fayez5,6, Katharigatta N Venugopala7,8, Abdelazim Ibrahim9,10.   

Abstract

The papain-like protease (PLpro ) is an important enzyme for coronavirus polyprotein processing, as well as for virus-host immune suppression. Previous studies reveal that a molecular analysis of PLpro indicates the catalytic activity of viral PLpro and its interactions with ubiquitin. By using sequence comparisons, molecular models, and protein-protein interaction maps, PLpro was compared in the three recorded fatal CoV epidemics, which involved severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), severe acute respiratory syndrome CoV (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV). The pairwise sequence comparison of SARS-CoV-2 PLpro indicated similarity percentages of 82.59% and 30.06% with SARS-CoV PLpro and MERS-CoV PLpro , respectively. In comparison with SARS-CoV PLpro , in SARS-CoV-2, the PLpro had a conserved catalytic triad of C111, H278, and D293, with a slightly lower number of polar interface residues and of hydrogen bonds, a higher number of buried interface sizes, and a lower number of residues that interact with ubiquitin and PLpro . These features might contribute to a similar or slightly lower level of deubiquitinating activity in SARS-CoV-2 PLpro. It was, however, a much higher level compared to MERS-CoV, which contained amino acid mutations and a low number of polar interfaces. SARS-CoV-2 PLpro and SARS-CoV PLpro showed almost the same catalytic site profiles, interface area compositions and polarities, suggesting a general similarity in deubiquitination activity. Compared with MERS-CoV, SARS-CoV-2 had a higher potential for binding interactions with ubiquitin. These estimated parameters contribute to the knowledge gap in understanding how the new virus interacts with the immune system.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; innate immunity; molecular modeling; papain-like protease

Year:  2020        PMID: 32902889     DOI: 10.1002/jmv.26497

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors.

Authors:  Daoqun Li; Junwen Luan; Leiliang Zhang
Journal:  Biochem Biophys Res Commun       Date:  2020-11-28       Impact factor: 3.575

2.  SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.

Authors:  Adam Stasiulewicz; Alicja W Maksymiuk; Mai Lan Nguyen; Barbara Bełza; Joanna I Sulkowska
Journal:  Int J Mol Sci       Date:  2021-04-12       Impact factor: 5.923

Review 3.  SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion.

Authors:  Zheng Yao Low; Nur Zawanah Zabidi; Ashley Jia Wen Yip; Ashwini Puniyamurti; Vincent T K Chow; Sunil K Lal
Journal:  Viruses       Date:  2022-09-08       Impact factor: 5.818

4.  GNPS-guided discovery of xylacremolide C and D, evaluation of their putative biosynthetic origin and bioactivity studies of xylacremolide A and B.

Authors:  Felix Schalk; Janis Fricke; Soohyun Um; Benjamin H Conlon; Hannah Maus; Nils Jäger; Thorsten Heinzel; Tanja Schirmeister; Michael Poulsen; Christine Beemelmanns
Journal:  RSC Adv       Date:  2021-05-24       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.